Tirzepatide Cost Without Insurance (2026)

See if you qualify — 5-minute assessment →
Online questionnaire · reviewed by a licensed clinician · 30-day money-back guarantee — a full refund on the 3-month and 6-month plans on 3-month and 6-month plans · cancel anytime

Tirzepatide cost without insurance — at a glance

Route to tirzepatide	Monthly cost (2026)	Notes
Zepbound vials — LillyDirect self-pay	$299–$449	2.5 mg $299 · 5 mg $399 · 7.5–15 mg $449 · Journey Program refill condition applies
Mounjaro (cash retail)	~$1,069+	No manufacturer self-pay vial discount; diabetes-labeled
Zepbound (list price)	~$1,086	Sticker price; few people pay this
Commercial insurance + savings card	as low as $25	Only if commercially insured and tirzepatide is covered
Compounded tirzepatide (telehealth)	~$125–$399	Not FDA-approved; not equivalent to Zepbound/Mounjaro; Nouri from $175/mo (6-mo plan)

Prices reflect publicly available information as of June 2026 and change frequently — verify current figures with the manufacturer, your provider, or your pharmacy before deciding. See our full GLP-1 cost guide for 2026 for a broader comparison across all weight-loss medications.

What is tirzepatide?

Tirzepatide is a once-weekly injectable prescription medication that acts on two gut hormone receptors — GIP and GLP-1 — to reduce appetite and promote weight loss. It is the active molecule in two brand-name drugs made by Eli Lilly: Mounjaro (FDA-approved for type 2 diabetes) and Zepbound (FDA-approved for chronic weight management in adults with obesity or overweight with a weight-related condition). Both are the same molecule at the same dose strengths; the difference is the FDA-approved indication and the resulting insurance coverage pathway.

Tirzepatide is a prescription-only medication. According to the NIDDK, prescription weight-loss medications are intended for adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition, and are meant to be used alongside diet and physical activity changes. A licensed provider determines eligibility on a case-by-case basis.

What the published research shows on tirzepatide

The most cited trial is SURMOUNT-1, published in the New England Journal of Medicine: in participants treated with tirzepatide (the branded molecule, not a compounded version), the maximum 15 mg dose produced a mean weight loss of approximately 20.9% of body weight over 72 weeks, compared to 3.1% with placebo. Jastreboff et al., NEJM 2022.

Important framing: these are results from a randomized controlled trial of the FDA-approved Zepbound/Mounjaro molecule. They are not results of any compounded tirzepatide product, and they are not a promised outcome for any individual patient or for any telehealth program. Individual results vary. This context is useful for understanding why tirzepatide commands a high list price — and why insurance coverage is hard-fought.

Without insurance: Zepbound self-pay vials are the brand cash route

Do not anchor on the ~$1,086 list price. Eli Lilly created a self-pay program specifically for uninsured or cash-pay patients: Zepbound single-dose vials, sold through LillyDirect (the company's direct-to-patient pharmacy), at a fixed price that is far below list.

As of June 2026 via the Zepbound self-pay pricing page (Lilly), the tiered prices are:

• 2.5 mg: ~$299/month
• 5 mg: ~$399/month
• 7.5 mg, 10 mg, 12.5 mg, 15 mg: ~$449/month

The Journey Program generally requires you to refill within approximately 45 days to maintain the self-pay rate. The vials are functionally equivalent to the auto-injector pen in terms of the medication delivered, but you draw and inject the dose yourself. Verify current tiers directly on LillyDirect before committing — pricing can change.

One practical note: vials require more preparation than auto-injector pens. For patients who prefer the pen format (which is covered by some insurance plans), the vial route may not be ideal. Talk to a provider about what format is appropriate.

Mounjaro vs Zepbound — why the cost differs

Mounjaro and Zepbound contain the same active molecule at the same dose strengths — both are tirzepatide made by Eli Lilly. The difference is FDA indication: Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management. That distinction drives major cost differences for uninsured patients:

• Zepbound: Lilly offers self-pay vials through LillyDirect at ~$299–$449/month.
• Mounjaro: No equivalent cash-vial discount. Without insurance, Mounjaro runs near its ~$1,069 list price (Lilly).

For someone seeking weight-loss treatment without insurance, Zepbound (the weight-loss label) is the lower-cost brand route. Mounjaro is primarily relevant for patients who have type 2 diabetes and whose insurance covers it on the diabetes indication. Using Mounjaro off-label for weight loss at retail prices is expensive compared to the Zepbound self-pay vial program.

Insurance, savings cards, and prior authorization

For people with commercial (employer or marketplace) insurance that covers tirzepatide, the landscape is different. Lilly's savings card program can reduce the copay to as little as $25/month for eligible commercially insured patients — a dramatic reduction from list.

The catch: tirzepatide coverage is far from universal. Historically, a large share of commercial plans have excluded weight-loss drugs from their formularies, and prior authorization is common. Many plans require documented BMI thresholds, comorbidities (such as type 2 diabetes, hypertension, or sleep apnea), and prior attempts at lifestyle intervention. Approval is not guaranteed. See our guide to how to get a GLP-1 covered by insurance for the step-by-step process.

For Medicare, a federal bridge program is expected to expand access: the CMS announced a Medicare GLP-1 Bridge that would provide access to qualifying GLP-1 medications for eligible Medicare beneficiaries. Review the current CMS announcement for up-to-date eligibility requirements and start dates, as these details are subject to change. For the broader question of whether insurance covers Zepbound or Wegovy, see our full guide: Does Insurance Cover Wegovy and Zepbound?

For Medicaid, coverage varies by state — a limited number of states cover GLP-1s for weight management; most do not. Eligibility and tier placement change frequently.

Compounded tirzepatide through telehealth: the lower-cost route (and what to know)

Compounded tirzepatide — made by state-licensed 503A compounding pharmacies and prescribed through telehealth providers — typically runs $125–$399/month.

Critical disclosure: Compounded tirzepatide is not FDA-approved. It is not the same as, and not therapeutically equivalent to, the brand-name drugs Zepbound or Mounjaro. Compounding pharmacies produce patient-specific formulations under state pharmacy law and FDA's human drug compounding framework; they are not subject to the same approval process as brand-name drugs. The FDA has raised concerns about compounded GLP-1 products — patients should review current FDA postmarket safety information and discuss compounding options with a licensed provider.

Compounded tirzepatide is prescribed only when a licensed clinician determines it is clinically appropriate for a specific patient. Not everyone who applies qualifies.

When comparing compounded providers, watch for pricing structures that obscure the true monthly cost:

• Membership fee structures: a $99/month "medication price" may come with a required $49–$79/month membership fee. Always compare the all-in monthly number.
• Dose-tier pricing: some providers charge more at higher doses; verify whether the price holds as you titrate.
• What's included: bare prescription vs. a program that includes clinician visits, nutrition support, and follow-up care.

For a side-by-side cost breakdown of compounded vs. brand options, see our guide: Compounded vs. Brand GLP-1 Cost.

Can you use FSA or HSA for tirzepatide?

Compounded GLP-1 medications prescribed for a qualifying medical purpose may be eligible for reimbursement through a Flexible Spending Account (FSA) or Health Savings Account (HSA) under IRC §213(d), which covers prescribed medications. Eligibility typically requires a valid prescription and, in some cases, a letter of medical necessity from your treating provider.

Important hedges: FSA/HSA reimbursement is not guaranteed — it depends on your specific plan's rules and your plan administrator's determination. Nouri does not accept FSA/HSA cards directly. If your plan allows reimbursement, you would pay out of pocket and submit for reimbursement with a receipt. Confirm the rules with your plan administrator and a tax professional before assuming coverage. For more detail, see our guide: Can You Use HSA/FSA for a GLP-1?

Where Nouri fits on cost

Nouri is a telehealth program that includes compounded GLP-1 treatment (when clinically prescribed), a personalized nutrition plan, a movement plan, and clinician-guided care — all at one transparent price with no separate membership fee:

Plan	Price	Billed as
Compounded tirzepatide — 6-month plan	$175/month	$1,050 every 6 months
Compounded tirzepatide — 3-month plan	$199/month	$597 every 3 months
Compounded tirzepatide — monthly	$225/month	$225/month, billed monthly

Any dose, same price. The medication is compounded by state-licensed 503A compounding pharmacies — Jungle Jim's Pharmacy (Fairfield, OH) and VialsRX. Nouri is LegitScript-certified and available in all 50 U.S. states.

When comparing telehealth providers on cost, compare the all-in monthly number. A "$99/month" teaser that adds a $49–$79 membership fee lands at $148–$178 all-in — a different picture than the headline rate. The Nouri price includes the full program: compounded GLP-1 when prescribed, nutrition plan, movement plan, and ongoing care access.

The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans.

What Nouri is not: Nouri's compounded tirzepatide is not FDA-approved and is not the same as, or therapeutically equivalent to, Zepbound or Mounjaro. The program does not guarantee specific weight-loss results. A licensed provider reviews each intake and prescribes medication only when clinically appropriate — not all applicants qualify.

For a broader look at how compounded and brand GLP-1 costs compare, see our full GLP-1 cost guide for 2026 and the Nouri GLP-1 telehealth pricing dataset, which tracks self-pay pricing across providers.

Start your 5-minute assessment →
Online questionnaire · reviewed by a licensed clinician · discreet home delivery · available in all 50 states

Related cost guides

• GLP-1 Cost Guide 2026 (All Options) — pricing pillar
• Zepbound Cost Without Insurance
• Compounded vs Brand GLP-1 Cost
• Cheapest Way to Get a GLP-1 (Cost Comparison)
• Tirzepatide vs Semaglutide
• Semaglutide Cost Guide

Frequently asked questions

How much does tirzepatide cost per month without insurance?

As of June 2026, brand tirzepatide self-pay (Zepbound vials via LillyDirect) is about $299–$449/month depending on dose. Compounded tirzepatide via telehealth typically runs $125–$399/month. The ~$1,086 list price is rarely what people pay. Compounded tirzepatide is not FDA-approved and not therapeutically equivalent to Zepbound or Mounjaro.

Is tirzepatide cheaper than semaglutide?

Roughly comparable at self-pay: brand tirzepatide (Zepbound vials) runs ~$299–$449/month vs brand semaglutide (Wegovy) ~$349/month. Compounded tirzepatide ($125–$399/month) tends to run somewhat higher than compounded semaglutide ($99–$199/month). Neither compounded form is FDA-approved. See our tirzepatide vs semaglutide comparison for a fuller breakdown.

Is Zepbound or Mounjaro cheaper?

For cash pay, Zepbound is cheaper. Lilly sells self-pay Zepbound vials at ~$299–$449/month via LillyDirect, while Mounjaro has no equivalent cash-vial discount and runs ~$1,000+ at retail. Both contain the same active molecule (tirzepatide), but with different FDA-approved indications and different cash-pay programs.

How much does Mounjaro cost without insurance?

Mounjaro (tirzepatide, FDA-approved for type 2 diabetes) has no manufacturer cash-vial discount, so without insurance it runs near its ~$1,069/month list price. For weight loss without insurance, the on-label Zepbound — with self-pay vials at ~$299–$449/month — is the lower-cost brand option.

Why is Mounjaro so expensive?

Mounjaro is the diabetes-labeled tirzepatide and has no manufacturer cash-vial discount like Zepbound's Journey Program. Without insurance it runs near the ~$1,069 list. For uninsured patients seeking weight-loss treatment, Zepbound's self-pay vials are the more accessible brand option at ~$299–$449/month.

How much is compounded tirzepatide?

Typically $125–$399/month via telehealth depending on the provider and their pricing structure. Compare all-in prices, not just the headline medication rate — membership fees can add $49–$79/month on top. Nouri's compounded tirzepatide starts at $175/month on the 6-month plan, with no separate membership fee. Compounded tirzepatide is not FDA-approved and is not therapeutically equivalent to Zepbound or Mounjaro.

Can you get tirzepatide without insurance?

Yes. Two main routes: LillyDirect self-pay Zepbound vials (~$299–$449/month; Journey Program conditions apply), or compounded tirzepatide through a telehealth provider (~$125–$399/month). No insurance is required for either. Compounded tirzepatide is not FDA-approved.

Does FSA or HSA cover tirzepatide?

Compounded GLP-1 medications may be eligible for FSA/HSA reimbursement under IRC §213(d) with a valid prescription and, in some cases, a letter of medical necessity. Eligibility varies by plan. Nouri does not accept FSA/HSA cards directly — reimbursement would require you to pay out of pocket and submit a claim. Confirm with your plan administrator and a tax professional before assuming coverage. See our full guide: Can You Use HSA/FSA for a GLP-1?

Sources and references

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022 (SURMOUNT-1) — Tier 1: primary trial
2. FDA Human Drug Compounding — fda.gov — Tier 1: regulatory framework
3. FDA GLP-1 Postmarket Safety Information — fda.gov — Tier 1: regulatory guidance
4. NIDDK — Prescription Medications to Treat Overweight and Obesity — Tier 1: NIH .gov
5. Zepbound self-pay vial pricing — Eli Lilly (pricinginfo.lilly.com) — Tier 3: manufacturer source; verify date
6. Mounjaro pricing — Eli Lilly (pricinginfo.lilly.com) — Tier 3: manufacturer source; verify date
7. GoodRx GLP-1 cost and savings guide — Tier 3: supporting context
8. CMS: Medicare GLP-1 Bridge Program — cms.gov — Tier 1: .gov
9. Nouri GLP-1 Telehealth Pricing Dataset 2026 — HuggingFace — self-cited original data

Medically reviewed by Amber Patel, MD · Nouri Editorial Team · Last reviewed June 29, 2026. Nouri content is reviewed by licensed clinicians and updated as pricing and guidance change.

Prices and coverage described here are accurate as of June 2026 and change frequently — verify current figures with the manufacturer, your pharmacy, your insurer, and (for HSA/FSA or tax questions) a tax professional before making decisions. This is general information, not medical, financial, or tax advice. A licensed provider determines individual eligibility; not all applicants qualify. Ozempic®, Wegovy®, and Rybelsus® are registered trademarks of Novo Nordisk; Mounjaro® and Zepbound® are registered trademarks of Eli Lilly; Nouri is not affiliated with, endorsed by, or sponsored by these companies. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as, or therapeutically equivalent to, the brand-name drugs. Published trial results cited in this article (e.g., SURMOUNT-1) reflect research on the branded tirzepatide molecule, not on Nouri's compounded product, and do not represent expected outcomes for any individual patient.